Cite
Enfortumab vedotin treatment regimens and efficacy in urothelial carcinoma: The Mayo Clinic experience.
MLA
Ballouz, Tara, et al. “Enfortumab Vedotin Treatment Regimens and Efficacy in Urothelial Carcinoma: The Mayo Clinic Experience.” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 627. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.4_suppl.627.
APA
Ballouz, T., Tripathi, N., Naqvi, S. A. A., Saxena, A., Bibi, A., Kase, A. M., Childs, D. S., Orme, J., Bryce, A. H., Riaz, I. B., & Singh, P. (2024). Enfortumab vedotin treatment regimens and efficacy in urothelial carcinoma: The Mayo Clinic experience. Journal of Clinical Oncology, 42, 627. https://doi.org/10.1200/JCO.2024.42.4_suppl.627
Chicago
Ballouz, Tara, Nikita Tripathi, Syed Arsalan Ahmed Naqvi, Akshat Saxena, Arifa Bibi, Adam McLain Kase, Daniel S Childs, et al. 2024. “Enfortumab Vedotin Treatment Regimens and Efficacy in Urothelial Carcinoma: The Mayo Clinic Experience.” Journal of Clinical Oncology 42 (February): 627. doi:10.1200/JCO.2024.42.4_suppl.627.